Cypher select stent
WebObjectives This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting … WebPatients received either a sirolimus-eluting stent (Cypher or Cypher Select, Cordis, Johnson & Johnson) or any commercially available uncoated stent. Patients, but not investigators, were unaware ...
Cypher select stent
Did you know?
WebThe company will also stop the manufacture of CYPHER ® and CYPHER SELECT ® Plus Sirolimus-Eluting Coronary Stents by the end of 2011. “Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market,” said ... WebThe CYPHER® Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. The next version of a sirolimus-eluting stent, the CYPHER SELECT Sirolimus-eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003.
WebSep 24, 2010 · Although this was an all-comers study, occurrence of very late stent thrombosis (VLST) events was very low: a cumulative 0.2% for BioMatrix Flex out to three years, compared with 0.9% for Cypher ... Web33 rows · Sep 14, 2024 · Cypher, Cypher Select; Cordis Corporation: Stainless steel: Parylene C primer, followed by a mixture of polyethylene-co-vinyl acetate (PEVA) and …
http://www.mrisafety.com/TMDL_view.php?editid1=4517 WebSep 1, 2003 · The CYPHER Stent represents a medical breakthrough treatment for patients with coronary artery disease, providing the potential for an effective, one-time treatment. With more than 40 clinical trials conducted or in progress worldwide, the CYPHER Stent remains the most studied drug-eluting stent today with the largest body of clinical …
WebHome - MagResource
WebThe CYPHER Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions … dynamic programming and recursionWebJun 18, 2024 · Eduardo Sousa implanted the first sirolimus-eluting stent in 1999 and it became available for clinical use as the CYPHER™ (Cordis) stent in 2002. CYPHER was ... associated with a significantly greater risk of stent thrombosis compared to the stainless-steel PP sirolimus-eluting stent CYPHER SELECT™ and the cobalt–chromium BP ... dynamic programming approachesWebLow Late Loss. Lower level of late loss achieved in the LEADERS trial with the BioMatrix Flex™ (Biolimus A9™) eluting stent at 9 months compared to the Cypher® Select™ stent 6; In Stent late loss in LEADERS = 0.13mm 6; Highest lipophilicity of the common limus drugs 1. Minimizes systemic exposure and reduces the drug circulating in the bloodstream crystal vs tcxoWebApr 15, 2002 · Cordis' clinical research program in drug-eluting stents involves 18 separate studies, making it the most extensive drug-eluting stent research program in the industry. To date, nearly 1,600 patients have been enrolled in CYPHER(TM) Sirolimus-eluting Stent clinical studies. More than 1,000 of the 1,600 have received the CYPHER(TM) Stent. dynamic programming and optimal control vol 2WebJun 26, 2006 · Cypher Select Plus boasts an enhanced delivery system with a short tip and flexible stent design. The new stent also features a novel hydrophilic coating that is … crystalvue coated do not polishWebCypher Select Sirolimus-Eluting Stent This information applies to all Cypher Stents manufactured in the U.S. Cordis, www.cordislabeling.com. Strength 1.5,3. Object Status … crystal vst vowelsWebCordis Corporation recently announced that it has received CE mark approval for the treatment of acute myocardial infarction (AMI) using the CYPHER® SELECT™ PLUS … crystal wacoche